Screener
Capricor Therapeutics CAPR Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| —— | —— | $0-100% | $0-100% | $0-100% | ||
| $28.87M+30.9% | $27.38M+44.7% | $23.13M+58.9% | $20.36M+72.4% | $22.05M+76.3% | ||
| $14.08M+148% | $9.4M+54.9% | $6.02M+41.0% | $5.92M+71.1% | $5.67M+85.4% | ||
| $42.95M+54.9% | $36.77M+47.2% | $29.16M+54.9% | $26.28M+72.1% | $27.72M+78.1% | ||
| -$42.95M-54.9% | -$36.77M-47.2% | -$29.16M-279% | -$26.28M-102% | -$27.72M-139% | ||
| $2.21M+22.4% | $2.83M+379% | —— | $1.71M+278% | $1.81M+206% | ||
| -$40.73M-57.2% | -$33.94M-39.2% | —— | —— | -$25.91M-156% | ||
| $1.6K0.0% | $0— | —— | —— | $1.6K+300% | ||
| -$40.73M-57.2% | -$33.94M-39.2% | -$30.17M-324% | -$24.57M-95.7% | -$25.91M-136% | ||
| -$0.70-22.8% | -$0.59-11.3% | -$0.62-464% | -$0.54-42.1% | -$0.57-62.9% | ||
| -$42.38M-55.6% | -$36.24M-47.4% | -$28.65M-291% | -$25.79M-104% | -$27.23M-142% | ||
| -$42.95M-54.9% | -$36.77M-47.2% | -$29.16M-279% | -$26.28M-102% | -$27.72M-139% |
FAQ
- Is Capricor Therapeutics profitable?
- Capricor Therapeutics is not currently profitable: it reported a net loss of $129.4M over the trailing twelve months, a -736.6% net margin.
- What is Capricor Therapeutics's earnings per share?
- Capricor Therapeutics's diluted EPS over the trailing twelve months is $-2.45.
- Where does Capricor Therapeutics's income statement data come from?
- Every line is extracted from Capricor Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.